|
시장보고서
상품코드
2054899
스타틴 시장 : 제품 유형별, 약제 클래스별, 적응증별(심근경색 예방), 스타틴 유형별, 제형별, 유효 성분 함유량별, 판매 채널별, 연령층별, 성별, 유통 채널별, 지역별Statins Market, By Product Type, By Drug Class, By Indication Prevention of Myocardial, By Type of Statin, By Formulation, By Strength, By Sales Channel, By Age Group, By Gender, By Distribution Channel, By Geography |
||||||
스타틴 시장은 2026년에 182억 2,000만 달러로 추정되고 있으며, 2033년까지 267억 2,000만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 5.6%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 182억 2,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년 예측 기간의 CAGR : | 5.60% | 2033년 시장 규모 예측 : | 267억 2,000만 달러 |
세계 스타틴 시장은 심혈관 치료제 분야에서 가장 중요한 의약품 부문 중 하나이며, 전 세계에서 심장병의 치료와 예방에 혁명을 일으킨 콜레스테롤 저하제를 포함하고 있습니다. 스타틴(과학적으로는 HMG-CoA 환원효소 억제제로 알려져 있습니다)은 간에서 콜레스테롤 합성에 관여하는 효소를 억제하여 작용함으로써, 저밀도 지단백(LDL) 콜레스테롤 수치를 효과적으로 낮추고 심혈관 질환의 위험 요인을 최소화합니다. 이 시장은 고콜레스테롤혈증 유병률의 증가, 심혈관 질환에 대한 의식의 향상, 그리고 전 세계적인 고령화 추세의 확산에 힘입어 인상적인 성장을 이루어 왔습니다.
이 시장에는 아토르바스타틴, 심바스타틴, 로스바스타틴, 프라바스타틴, 로바스타틴 등 다양한 환자의 요구에 부응하기 위해 여러 제형과 용량으로 제공되는 다양한 스타틴 제제가 포함됩니다. 심혈관 질환이 여전히 전 세계 주요 사망 원인인 가운데, 스타틴은 주요 심혈관 사건을 감소시키는 효과가 광범위한 임상적 근거에 의해 입증되어, 1차 예방 및 2차 예방 전략 모두에서 핵심 약물로 자리 잡고 있습니다. 시장 상황의 특징은 브랜드 의약품과 제네릭 의약품이 모두 존재한다는 점이며, 특허 만료는 가격 동향에 큰 영향을 미치는 동시에 전 세계 다양한 경제적 계층의 환자들이 의약품을 더 쉽게 구할 수 있도록 하고 있습니다.
시장 역학
세계 스타틴 시장은 몇 가지 강력한 촉진요인에 힘입어 성장하고 있습니다. 특히 선진국과 개발도상국에서 앉아 있는 생활 습관, 불건전한 식생활, 비만율의 증가가 지속되는 가운데, 심혈관 질환 및 고콜레스테롤혈증의 유병률 상승이 주요 성장 동력이 되고 있습니다. 심혈관 합병증의 위험이 본질적으로 높은 고령 인구의 증가는 콜레스테롤 저하 요법에 대한 지속적인 수요를 창출하고 있으며, 한편으로는 의료비 증가와 보험 적용 범위 확대가 시장 접근성을 높이고 있습니다. 헬스케어에 대한 인식이 높아지고 정기적인 콜레스테롤 검사 프로그램이 보급됨에 따라 조기 진단과 치료 시작이 확대되면서, 스타틴 치료가 필요한 환자층이 더욱 늘어나고 있습니다.
그러나 시장에는 중대한 제약도 존재합니다. 주요 스타틴 계열 약물의 특허 만료에 따라 제네릭 의약품이 널리 보급되면서 가격 경쟁이 심화되고, 제약사의 이익률이 압박받고 있습니다. 근육 관련 증상, 간 효소 수치 상승, 당뇨병 발병 위험 등 스타틴과 관련된 부작용에 대한 안전성 우려가 일부 의사와 환자들 사이에서 주저함을 낳고 있으며, 이는 처방 양상에 영향을 미치고 있습니다. 또한 PCSK9 억제제나 새로운 지질 개선제를 포함한 대체 콜레스테롤 저하 요법의 등장은 기존의 스타틴 요법에 있으며, 경쟁상 과제가 되고 있습니다. 신규 제제나 적응증에 대한 규제의 복잡성과 엄격한 승인 절차는 시장 진입과 혁신의 걸림돌이 되고 있습니다. 그럼에도 불구하고 효능을 높이는 동시에 부작용을 줄일 수 있는 병용 요법의 개발, 의료 인프라가 점차 정비되고 있는 신흥 시장으로의 진출, 그리고 콜레스테롤 관리 이상의 스타틴의 새로운 용도 모색(염증 완화 및 신경 보호에 대한 잠재적 이점 등)을 통해 치료의 범위와 시장의 잠재력을 크게 확대할 수 있는 큰 기회가 존재합니다.
본 조사의 주요 특징.
- 본 조사에서는 다양한 부문의 잠재적 매출 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업이 채택하는 경쟁 전략에 관한 중요 인사이트를 제공합니다.
- 본 조사에서는 다음의 주요 항목(기업 개요, 제품 포트폴리오, 주요 성과, 재무 실적, 전략)을 바탕으로 전 세계 스타틴 시장의 주요 기업 개요을 소개합니다.
- 이 보고서의 분석 결과를 바탕으로, 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 충분한 정보를 바탕으로 의사결정을 내릴 수 있게 됩니다.
- 본 스타틴 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 스타틴 시장 분석에 활용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 스타틴 시장 : 제품 유형별, 2021-2033년
제5장 세계의 스타틴 시장 : 약제 클래스별, 2021-2033년
제6장 세계의 스타틴 시장 : 적응증별, 2021-2033년
제7장 세계의 스타틴 시장 : 스타틴 유형별, 2021-2033년
제8장 세계의 스타틴 시장 : 제제별, 2021-2033년
제9장 세계의 스타틴 시장 : 강도별, 2021-2033년
제10장 세계의 스타틴 시장 : 판매 채널별, 2021-2033년
제11장 세계의 스타틴 시장 : 연령층별, 2021-2033년
제12장 세계의 스타틴 시장 : 성별, 2021-2033년
제13장 세계의 스타틴 시장 : 유통 채널별, 2021-2033년
제14장 세계의 스타틴 시장 : 지역별, 2021-2033년
제15장 경쟁 구도
제16장 애널리스트의 제안
제17장 참고 문헌 및 조사 방법
KSA 26.06.18Statins Market is estimated to be valued at USD 18.22 Bn in 2026 and is expected to reach USD 26.72 Bn by 2033, growing at a compound annual growth rate (CAGR) of 5.6% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 18.22 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.60% | 2033 Value Projection: | USD 26.72 Bn |
The global statins market represents one of the most significant pharmaceutical segments in cardiovascular therapeutics, encompassing cholesterol-lowering medications that have revolutionized the treatment and prevention of heart disease worldwide. Statins, scientifically known as HMG-CoA reductase inhibitors, function by blocking the enzyme responsible for cholesterol synthesis in the liver, effectively reducing low-density lipoprotein (LDL) cholesterol levels and minimizing cardiovascular risk factors. This market has experienced substantial growth driven by the increasing prevalence of hypercholesterolemia, rising awareness of cardiovascular diseases, and expanding geriatric population globally.
The market encompasses various statin formulations including atorvastatin, simvastatin, rosuvastatin, pravastatin, and lovastatin, available in multiple dosage forms and strengths to cater to diverse patient needs. With cardiovascular diseases remaining the leading cause of mortality worldwide, statins have become cornerstone medications in both primary and secondary prevention strategies, supported by extensive clinical evidence demonstrating their efficacy in reducing major adverse cardiovascular events. The market landscape is characterized by the presence of both branded and generic formulations, with patent expirations having significantly impacted pricing dynamics while simultaneously improving accessibility for patients across different economic segments globally.
Market Dynamics
The global statins market is propelled by several compelling drivers, with the escalating prevalence of cardiovascular diseases and hypercholesterolemia serving as primary growth catalysts, particularly as sedentary lifestyles, unhealthy dietary patterns, and obesity rates continue to rise across developed and developing nations. The expanding geriatric population, who are inherently at higher risk for cardiovascular complications, creates sustained demand for cholesterol-lowering therapies, while increasing healthcare expenditure and improved insurance coverage enhance market accessibility. Growing awareness about preventive healthcare measures and routine cholesterol screening programs have led to earlier diagnosis and treatment initiation, further expanding the patient pool requiring statin therapy.
However, the market faces significant restraints including the widespread availability of generic alternatives following patent expirations of major branded statins, which has intensified price competition and compressed profit margins for pharmaceutical companies. Safety concerns related to statin-associated adverse effects such as muscle-related symptoms, liver enzyme elevations, and potential diabetes risk have created hesitancy among some physicians and patients, impacting prescription patterns. Additionally, the emergence of alternative cholesterol-lowering therapies, including PCSK9 inhibitors and newer lipid-modifying agents, poses competitive challenges to traditional statin therapy. Regulatory complexities and stringent approval processes for new formulations or indications create barriers to market entry and innovation. Nevertheless, substantial opportunities exist through the development of combination therapies that enhance efficacy while potentially reducing side effects, expansion into emerging markets with growing healthcare infrastructure, and the exploration of novel statin applications beyond cholesterol management, including potential benefits in inflammation reduction and neuroprotection, which could significantly broaden the therapeutic scope and market potential.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global statins market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Pfizer Inc, AstraZeneca, Merck & Co, Novartis AG, Medicure Inc., Teva Pharmaceutical, Mylan NV, Sun Pharmaceutical, Aurobindo Pharma, Dr. Reddy's Laboratories, Kowa Pharmaceuticals, and other prominent players.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global statins market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global statins market.
Market Segmentation
- Product Type Insights (Revenue, USD Bn, 2021 - 2033)
- Generic Drugs
- Branded Drugs
- Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Atorvastatin
- Fluvastatin
- Lovastatin
- Pravastatin
- Rosuvastatin
- Simvastatin
- Pitavastatin
- Indication Insights (Revenue, USD Bn, 2021 - 2033)
- Prevention of Myocardial Infarction
- Stroke Prevention
- Type 2 Diabetes-related MI and Stroke Prevention
- Coronary Heart Disease Risk Reduction
- Primary Hyperlipidemia Treatment
- Mixed Dyslipidemia Treatment
- Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
- Type Of Statin Insights (Revenue, USD Bn, 2021 - 2033)
- Natural Statins
- Synthetic Statins
- Formulation Insights (Revenue, USD Bn, 2021 - 2033)
- Tablets
- Capsules
- Strength Insights (Revenue, USD Bn, 2021 - 2033)
- 10 mg
- 20 mg
- 40 mg
- 80 mg
- Sales Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Prescription
- Over-the-Counter
- Age Group Insights (Revenue, USD Bn, 2021 - 2033)
- Pediatric
- Adult
- Geriatric
- Gender Insights (Revenue, USD Bn, 2021 - 2033)
- Male
- Female
- Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- AstraZeneca
- Merck & Co
- Novartis AG
- Medicure Inc.
- Teva Pharmaceutical
- Mylan NV
- Sun Pharmaceutical
- Aurobindo Pharma
- Reddy's Laboratories
- Kowa Pharmaceuticals
- Other Prominent Players
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Statins Market, By Product Type
- Global Statins Market, By Drug Class
- Global Statins Market, By Indication
- Global Statins Market, By Type of Statin
- Global Statins Market, By Formulation
- Global Statins Market, By Strength
- Global Statins Market, By Sales Channel
- Global Statins Market, By Age Group
- Global Statins Market, By Gender
- Global Statins Market, By Distribution Channel
- Global Statins Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Statins Market, By Product Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Generic Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Branded Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Statins Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Atorvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Fluvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Lovastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pravastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Rosuvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Simvastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pitavastatin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Statins Market, By Indication, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Prevention of Myocardial Infarction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Type 2 Diabetes-related MI and Stroke Prevention
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Coronary Heart Disease Risk Reduction
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Primary Hyperlipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Mixed Dyslipidemia Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Hypertriglyceridemia and Primary Dysbetalipoproteinemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Homozygous Familial Hypercholesterolemia (HoFH) Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Heterozygous Familial Hypercholesterolemia (HeFH) Treatment (Pediatric)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Statins Market, By Type of Statin, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Natural Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Synthetic Statins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
8. Global Statins Market, By Formulation, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Tablets
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Capsules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
9. Global Statins Market, By Strength, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- 10 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 40 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- 80 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
10. Global Statins Market, By Sales Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Prescription
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Over-the-Counter
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
11. Global Statins Market, By Age Group, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Pediatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
12. Global Statins Market, By Gender, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
13. Global Statins Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
14. Global Statins Market, By Region, 2021 - 2033, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product Type, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Drug Class, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Type of Statin, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Formulation, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Strength, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Sales Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
15. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Medicure Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Mylan NV
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sun Pharmaceutical
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Aurobindo Pharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Reddy's Laboratories
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kowa Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Other Prominent Players
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
16. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
17. References and Research Methodology
- References
- Research Methodology
- About us
